Blood-based tumor gene mutation burden useful for predicting overall survival in non-small cell lung cancer
Blood-based TMB analysis, combined with specific gene mutation identification, predicts treatment success and enhances overall survival in non-small cell lung cancer patients by guiding treatment decisions with durvalumab and tremelimumab.
Patent Information
- Application Number
- JP2024140635
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-08-20
- Filing Date
- 2024-08-22
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current methods fail to establish a correlation between tumor mutational burden (TMB) in blood and overall survival in non-small cell lung cancer patients treated with anti-PD-1/L1 antibodies, limiting the predictive power for treatment success.
Determine tumor mutational burden (TMB) in patients using blood-based analysis to predict treatment success with durvalumab, tremelimumab, and chemotherapeutic agents, identifying specific gene mutations like ARID1A, STK11, and KEAP1 to guide treatment decisions.
Enhances the prediction of overall survival and treatment efficacy by identifying patient subpopulations with high bTMB, improving outcomes in non-small cell lung cancer patients treated with durvalumab and tremelimumab, particularly those with mutations in ARID1A, STK11, and KEAP1.
Smart Images

Figure 2024161577000001_ABST
Abstract
Description
[Technical field]
[0001] The present disclosure generally relates to methods of treating patients with non-small cell lung cancer based on the use of blood-based tumor mutational burden to predict overall survival of patients treated with durvalumab and / or tremelimumab and / or chemotherapeutic agents. The present disclosure also relates to methods of treating patients with non-small cell lung cancer based on the identification of mutations in circulating tumor DNA associated with sensitivity or resistance to immunotherapy. [Background technology]
[0002] Patients with non-small cell lung cancer ("NSCLC") with high pretreatment tumor mutational burden ("TMB") have demonstrated improved outcomes after treatment with immune checkpoint inhibitors (Yarchoan et al., N. Engl. J. Med. 377(25):2500-01(2017); Snyder et al., N. Engl. J. Med. 371(23):2189-99(2014); Le et al., Science 357(6349):409-13(2017); Rizvi et al., Science 348(6230):124-28(2015); Rizvi et al., J. Clin. Oncol. 36(7):633-41(2018); Hellmann et al., Cancer Cell 33(5):843-52(2018); Carbone ... al., N. Engl. J. Med. 376(25):2415-26(2017); Hellmann et al., N. Engl. J. Med. 378(22):2093-104(2018)). TMB measured in blood has also emerged as a novel and promising approach to enhance response to PD-1 / L1 therapy in NSCLC patients (Gandara et al., Ann. Oncol. 28(Suppl 5):v460-v496(2017); Planchard et al., Ann. Oncol. 29(Suppl 4):iv192-iv237(2018)). Reports have shown that NSCLC patients with high blood TMB ("bTMB") have improved progression-free survival and response rates in both first-line and second-line treatment. However, no correlation has been shown between either tissue TMB ("tTMB") or bTMB and overall survival in NSCLC patients treated with anti-PD-1 / L1 antibodies. Summary of the Invention [Means for solving the problem]
[0003] The present disclosure provides a method of predicting successful cancer treatment in a patient in need thereof, the method comprising determining the tumor mutation burden (TMB) of the patient, where high TMB predicts successful treatment.
[0004] The disclosure also provides a method of treating cancer in a patient in need thereof, comprising the steps of: (a) determining the patient's TMB; (b) determining whether the TMB is high or low; and (c) administering or continuing treatment if the TMB is high, or not administering or discontinuing treatment if the TMB is low.
[0005] The disclosure further provides a method of predicting successful cancer treatment in a patient in need thereof, the method comprising determining whether the patient has a somatic mutation in the AT-rich interaction domain-containing protein 1A gene (ARID1A), where success of the treatment is predicted if a somatic mutation is present.
[0006] The disclosure further provides a method of treating cancer in a patient in need thereof, comprising: (a) determining whether the patient has a somatic mutation in at least one of the serine / threonine kinase 11 gene (STK11), Kelch-like ECH binding protein 1 gene (KEAP1), AT-rich interaction domain-containing protein 1A gene (ARID1A), or K-Ras gene; and (b) administering or continuing treatment if the patient has a somatic mutation in at least one of the serine / threonine kinase 11 gene (STK11), Kelch-like ECH binding protein 1 gene (KEAP1), AT-rich interaction domain-containing protein 1A gene (ARID1A), or K-Ras gene.
[0007] Other features and advantages of the disclosure will become apparent from the detailed description and the claims. [Brief description of the drawings]
[0008] [Figure 1-1] A list of genes included in the TMB analysis is shown. [Figure 1-2] Continued from Figure 1-1. [Diagram 2] Overall survival of patients with PD-L1 expression in ≥25% of tumour cells (TC) treated with durvalumab (D) versus chemotherapy (CT), or durvalumab and tremelimumab (D+T) versus chemotherapy (CT). [Diagram 3] Progression-free survival (PFS) is shown for patients with PD-L1 expression in ≥25% of tumor cells (TC) treated with durvalumab versus chemotherapy, or durvalumab and tremelimumab versus chemotherapy. [Figure 4] Primary analysis population is shown. Analyses were performed using Cox proportional hazards models with covariates of duration of treatment and subgroups of interest. Subgroups were by sex, age, immune cell PD-L1 expression, histology, smoking history, and race. Subgroup analyses by performance status were post hoc. *97.54% CI is shown. [Diagram 5] Correlation between two TMB measurement tools in the MYSTIC study. The correlation plot is based on TMB data from 352 patients with matched blood and tissue. The baseline has been estimated using linear regression. [Figure 6A] Overall survival is shown in the ITT population and in populations evaluable for blood and tissue TMB. [Figure 6B] Overall survival is shown in the ITT population and in populations evaluable for blood and tissue TMB. [Figure 6C] Overall survival is shown in the ITT population and in populations evaluable for blood and tissue TMB. [Figure 7] Analysis of overall survival across blood TMB cutoff values is shown. [Figure 8] Blood TMB indicates overall survival for patients with >= 16mut / Mb and < 16mut / Mb. [Figure 9]Venn diagram showing the intersection of patient subgroups based on blood TMB and PD-L1. *Percentages are calculated from the intent-to-treat population (all randomized patients; N=1118). [Figure 10] Overall survival rates for patients with blood TMB ≥ 20mut / Mb and < 20mut / Mb are shown. [Figure 11] Progression-free survival (PFS) for patients with blood TMB ≥ 20mut / Mb and < 20mut / Mb is shown. [Figure 12A] Overall survival rates for patients with blood TMB ≥ 10 mut / Mb and < 10 mut / Mb are shown. [Figure 12B] Overall survival rates for patients with blood TMB ≥ 10 mut / Mb and < 10 mut / Mb are shown. [Figure 13] The TMB algorithm is shown below. [Figure 14] Overall survival (OS) of patients with PD-L1 expression in tumor cells (TC) ≥ 50%) treated with durvalumab and tremelimumab (D+T) versus chemotherapy (CT) is shown. [Figure 15] Overall survival (OS) of patients with PD-L1 expression in tumor cells (TC) ≥ 1%) treated with durvalumab and tremelimumab (D+T) versus chemotherapy (CT) is shown. [Figure 16] Combining high bTMB or tumor cells (TC) <1% shows improved morbidity but reduced efficacy. [Figure 17] Combining high bTMB or tumor cells (TC) ≥ 25% shows improved morbidity but reduced efficacy. [Figure 18] Prevalence of mutations in the genes KEAP1, STK11, and ARID1A among patients in the MYSTIC study. 324 patients (out of 943 evaluable) had a mutation in one of the three genes KEAP1, STK11, or ARID1A. [Figure 19]Prevalence of mutations by histology and treatment is shown. STK11 and KEAP1 mutations were more prevalent in patients with non-squamous histology compared with patients with squamous histology. Prevalence of STK11, KEAP1, and ARID1A mutations was balanced between treatment groups. [Figure 20] The prevalence of mutations according to bTMB status is shown. [Figure 21] The prevalence of mutations according to PD-L1 expression is shown. [Figure 22] Objective response rates of treatment with durvalumab and tremelimumab (durvalumab + tremelimumab), durvalumab monotherapy (durvalumab), or chemotherapy are shown according to the patient's mutational status. [Figure 23] Overall survival of KEAP1m vs. KEAP1wt in all mutation-evaluable patients treated with durvalumab and tremelimumab, durvalumab monotherapy, or chemotherapy. Patients treated with durvalumab and tremelimumab, durvalumab monotherapy, or chemotherapy were included in each group; m=mutation positive; mOS=median overall survival; wt=wild type. [Figure 24] FIG. 1 shows overall survival of KEAP1m vs. KEAP1wt in patients treated with durvalumab monotherapy vs. chemotherapy, or durvalumab + tremelimumab vs. chemotherapy. [Diagram 25] Overall survival of STK11m vs. STK11wt in all mutation-evaluable patients. Each group included patients treated with durvalumab and tremelimumab, durvalumab monotherapy, or chemotherapy. [Figure 26] FIG. 1 shows overall survival of STK11m vs. STK11wt in patients treated with durvalumab monotherapy vs. chemotherapy, or durvalumab + tremelimumab vs. chemotherapy. [Figure 27] Overall survival of STK11m / KEAP1m vs. wild type and STK11m / KRASm vs. wild type in all mutation-evaluable patients. Patients treated with durvalumab and tremelimumab, durvalumab monotherapy, or chemotherapy were included in each group. [Figure 28] Overall survival for ARID1Am and ARID1Awt in all patients evaluable for mutations. Each group included patients treated with durvalumab and tremelimumab, durvalumab monotherapy, or chemotherapy. [Figure 29] FIG. 1 shows overall survival of ARID1Am vs. ARID1wt in patients treated with durvalumab monotherapy vs. chemotherapy, or durvalumab + tremelimumab vs. chemotherapy. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0009] The present disclosure generally relates to methods of treating patients with non-small cell lung cancer based on the use of blood-based tumor mutational burden to predict overall survival of patients treated with durvalumab and / or tremelimumab and / or chemotherapeutic agents. The present disclosure also relates to methods of treating patients with non-small cell lung cancer based on the identification of mutations in circulating tumor DNA (ctDNA) associated with sensitivity or resistance to immunotherapy.
[0010] The present disclosure is based, at least in part, on the identification of unique patient subpopulations by bTMB. As described herein, for durvalumab treatment in combination with tremelimumab, bTMB was more predictive of overall survival than the level of PD-L1 expression. In some embodiments, for durvalumab monotherapy treatment + / - chemotherapy agents, bTMB is also more predictive of overall survival than the level of PD-L1 expression. In further embodiments, for durvalumab treatment in combination with tremelimumab + / - chemotherapy agents, bTMB is more predictive of overall survival than the level of PD-L1 expression.
[0011] As used in accordance with this disclosure, unless otherwise indicated, all technical and scientific terms shall be understood to have the same meaning as commonly understood by one of ordinary skill in the art. Unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.
[0012] In some embodiments, provided herein is a method of predicting successful treatment of cancer in a patient in need thereof, the method comprising determining a tumor mutational burden (TMB) of the patient, wherein a high TMB predicts successful treatment.
[0013] "Tumor mutational burden" or "TMB" refers to the amount of mutations found in a tumor. TMB varies among different tumor types. Some tumor types have a higher mutation rate than others. TMB can be measured by various tools known in the art. In certain embodiments, these tools are Foundation Medicine and Guardant Health measurement tools. As described herein, evaluation of potential neoantigens encoding mutations in a set of specific genes has been found to correlate with treatment with durvalumab in combination with tremelimumab. Determining whether a tumor has a high or low level of tumor mutational burden can be done by comparing to a reference population with similar tumors and determining the median or mean level of expression. In some embodiments, high TMB is defined as ≧12 to ≧20 mutations / megabase (mut / Mb). In other embodiments, high TMB is defined as ≧16 mutations / megabase (mut / Mb). In other embodiments, high TMB is defined as ≧20 mutations / megabase (mut / Mb).
[0014] As used herein, the term "MYSTIC" refers to Study NCT02453282, which is a Phase III, open-label, first-line trial of durvalumab with or without tremelimumab versus standard of care in NSCLC.
[0015] In some embodiments, the method includes treatment with durvalumab. The term "durvalumab" as used herein refers to an antibody that selectively binds to PD-L1 and blocks PD-L1 binding to the PD-1 receptor and the CD80 receptor, as disclosed in U.S. Patent No. 9,493,565 (referred to as "2.14H9OPT"), which is incorporated herein by reference in its entirety. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation within the constant domain of the IgG1 heavy chain. This reduces binding to complement component C1q and the Fcγ receptor responsible for mediating antibody-dependent cell-mediated cytotoxicity ("ADCC"). Durvalumab can relieve PD-L1-mediated suppression of human T-cell activation in vitro and inhibits tumor growth in xenograft models by a T-cell-dependent mechanism.
[0016] In some embodiments, the methods disclosed herein include treatment with tremelimumab. The term "tremelimumab" as used herein refers to an antibody that selectively binds to CTLA-4 polypeptide, as disclosed in U.S. Pat. No. 8,491,895 (referred to as "clone 11.2.1"), which is incorporated herein by reference in its entirety. Tremelimumab is specific for human CTLA-4 and has no cross-reactivity with related human proteins. Tremelimumab blocks the inhibitory effect of CTLA-4, thus enhancing T cell activation. Tremelimumab shows minimal specific binding to Fc receptors, does not induce natural killer (NK) ADCC activity, and does not deliver inhibitory signals after binding to and agglutinating on plates.
[0017] In some embodiments, the methods disclosed herein include treatment with a chemotherapeutic agent comprising at least one of Abraxane, carboplatin, gemcitabine, cisplatin, pemetrexed, or paclitaxel. In some embodiments, the chemotherapeutic agent comprises Abraxane + carboplatin, gemcitabine + cisplatin, gemcitabine + carboplatin, pemetrexed + carboplatin, pemetrexed + cisplatin, or paclitaxel + carboplatin.
[0018] In some embodiments, the methods disclosed herein include treatment with durvalumab, tremelimumab, and a chemotherapeutic agent. In other embodiments, the methods disclosed herein include treatment with durvalumab and a chemotherapeutic agent. In other embodiments, the methods disclosed herein include treatment with durvalumab.
[0019] In some embodiments, the patient has a somatic mutation in at least one of the serine / threonine kinase 11 gene (STK11), the Kelch-like ECH-binding protein 1 gene (KEAP1), the AT-rich interaction domain-containing protein 1A gene (ARID1A), or the K-Ras gene. STK11 and KEAP1 mutation status were prognostic factors for OS in patients with metastatic non-small cell lung cancer (mNSCLC). In some embodiments, mNSCLC with STK11 or KEAP1 mutations is prognostic for shorter OS compared to patients with mNSCLC with STK11 or KEAP1 wild type. In some embodiments, ARID1A mutations are used as a biomarker to predict improved OS in patients receiving durvalumab + tremelimumab treatment.
[0020] The term "ARID1A" encompasses "full-length" unprocessed ARID1A and any form of ARID1A that results from processing in a cell. The term also encompasses naturally occurring variants of ARID1A, such as splice variants or allelic variants.
[0021] The term "KEAP1" encompasses "full-length," unprocessed KEAP1, and any form of KEAP1 that results from processing in a cell. The term also encompasses naturally occurring variants of KEAP1, such as splice variants or allelic variants.
[0022] The term "STK11" encompasses "full-length," unprocessed STK11, and any form of STK11 that results from processing in a cell. The term also encompasses naturally occurring variants of STK11, such as splice variants or allelic variants.
[0023] The term "K-Ras" encompasses "full-length" unprocessed K-Ras and any form of K-Ras that results from processing in a cell. The term also encompasses naturally occurring variants of K-Ras, such as splice variants or allelic variants.
[0024] In some embodiments, there is provided a method of treating cancer in a patient in need thereof, comprising: (a) determining the TMB of the patient; (b) determining whether the TMB is high or low; and (c) treating or continuing treatment if TMB is high, or not treating or discontinuing treatment if TMB is low. Provided herein is a method comprising:
[0025] Determining whether TMB is high may vary depending on the tumor type. Determining whether a tumor has a high or low level of tumor mutation burden can be done by comparing with a reference population with similar tumors and determining the median or mean level of expression. In some embodiments, the level of TMB is divided into low (1-5 mutations / mb), intermediate (6-15 mutations / mb), and high (≧16 mutations / mb).
[0026] In some embodiments, the success of treatment is determined by an increase in OS when compared to standard of care. "Standard of care" (SOC) and "platinum-based chemotherapy" refer to chemotherapy treatments that include at least one of Abraxane, carboplatin, gemcitabine, cisplatin, pemetrexed, or paclitaxel. In some embodiments, SOC includes Abraxane + carboplatin, gemcitabine + cisplatin, gemcitabine + carboplatin, pemetrexed + carboplatin, pemetrexed + cisplatin, or paclitaxel + carboplatin.
[0027] As used herein, overall survival ("OS") refers to the period beginning on the date of treatment until death from any cause. OS may refer to the overall survival rate within a period such as, for example, 12 months, 18 months, and 24 months.
[0028] In some embodiments, provided herein is a method of predicting successful treatment of cancer in a patient in need thereof, the method comprising determining whether the patient has a somatic mutation in AT-rich interaction domain-containing protein 1A gene (ARID1A), wherein successful treatment is predicted if there is a somatic mutation.
[0029] In some embodiments, provided herein is a method of treating cancer in a patient in need thereof, comprising: (a) determining whether the patient has a somatic mutation in at least one of the serine / threonine kinase 11 gene (STK11), Kelch-like ECH binding protein 1 gene (KEAP1), AT-rich interaction domain-containing protein 1A gene (ARID1A), or K-Ras gene; and (b) administering or continuing treatment if the patient has a somatic mutation in at least one of the serine / threonine kinase 11 gene (STK11), Kelch-like ECH binding protein 1 gene (KEAP1), AT-rich interaction domain-containing protein 1A gene (ARID1A), or K-Ras gene.
[0030] The term "patient" is intended to include human and non-human animals, particularly mammals.
[0031] In some embodiments, the methods disclosed herein relate to treating a subject for a tumor disorder and / or a cancer disorder. In some embodiments, the cancer is selected from melanoma, breast cancer, pancreatic cancer, lung cancer (e.g., non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)), hepatocellular carcinoma, cholangiocarcinoma or biliary tract cancer, gastric cancer, esophageal cancer, head and neck cancer, renal cancer, cervical cancer, colorectal cancer, or urothelial bladder cancer.
[0032] The term "treatment" or "treating" as used herein refers to therapeutic treatment. Those in need of treatment include subjects with cancer. In some embodiments, the methods disclosed herein can be used to treat tumors. In other embodiments, treating tumors includes inhibiting tumor growth, promoting tumor reduction, or both inhibiting tumor growth and promoting tumor reduction.
[0033] The term "administration" or "administering," as used herein, refers to providing, contacting, and / or delivering one or more compounds by any suitable route to achieve a desired effect. Administration may include, but is not limited to, oral, sublingual, parenteral (e.g., intravenous, subcutaneous, intradermal, intramuscular, intra-articular, intra-arterial, intrasynovial, intrasternal, intrathecal, intralesional, or intracranial injection), transdermal, topical, buccal, rectal, vaginal, nasal, ocular, by inhalation, and by implant.
[0034] The term "pharmaceutical composition" or "therapeutic composition," as used herein, refers to a compound or composition capable of inducing a desired therapeutic effect when properly administered to a subject. In some embodiments, the present disclosure provides a pharmaceutical composition comprising a pharma- ceutical acceptable carrier and a therapeutically effective amount of at least one antibody of the present disclosure.
[0035] Without limiting the disclosure, several embodiments of the disclosure are described below for purposes of illustration. EXAMPLES
[0036] The following examples are illustrative of certain embodiments of the present disclosure and various uses thereof, they are provided for illustrative purposes only and should not be construed as limiting the scope of the invention in any way.
[0037] Example 1: Durvalumab with or without tremelimumab in metastatic non-small cell lung cancer The MYSTIC trial described herein was a phase 3 study comparing durvalumab with or without tremelimumab to platinum-based chemotherapy as first-line treatment of metastatic NSCLC.
[0038] patient Adult patients with stage IV NSCLC were eligible if they had not received prior systemic therapy for advanced / metastatic NSCLC, had Eastern Cooperative Oncology Group performance status of 0–1, measurable disease by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) (Chaft et al., Cancer Res. 78(13 Suppl)(abstr.CT113)(2018)), and known tumor PD-L1 expression status before randomization. Patients with sensitizing EGFR mutations or ALK rearrangements and those with symptomatic unstable brain metastases were excluded.
[0039] Study Design and Treatment Patients were stratified by PD-L1 TC ≥25% vs <25% and histology and randomized 1:1:1 to receive durvalumab 20 mg / kg every 4 weeks, durvalumab 20 mg / kg plus tremelimumab 1 mg / kg every 4 weeks (up to 4 doses), or platinum-doublet chemotherapy for 4 to 6 cycles. Patients continued treatment until objective disease progression (by RECIST v1.1), adverse events (AEs) requiring discontinuation of treatment, or consent withdrawal.
[0040] Evaluation items and assessment The primary endpoints were overall survival (OS; time from randomization to death from any cause) for both immunotherapy arms compared to chemotherapy, and progression-free survival (PFS; time from randomization to objective disease progression or death by blinded independent central review [BICR]) for durvalumab plus tremelimumab compared to chemotherapy, all in patients with PD-L1 TC ≥ 25%. Primary endpoints were to be evaluated in patients with PD-L1 TC ≥ 25%. Secondary endpoints included PFS for durvalumab vs chemotherapy, objective response rate (ORR) and duration of response (DOR) for both immunotherapy arms compared to chemotherapy (all in patients with PD-L1 TC ≥ 25%), and safety and tolerability. Relationships between biomarkers, including TMB, and clinical outcomes were also assessed.
[0041] PD-L1 expression was assessed at a central laboratory using the VENTANA PD-L1 (SP263) immunohistochemistry (IHC) assay (Ventana Medical Systems, Tucson, AZ, USA) using multiple cutoff values (Rebelatto et al., Diagn. Pathol. 11(1):95(2016)). Tumor samples obtained within 3 months prior to screening were accepted. Analytical results showed strong concordance across the dynamic range between the Dako PD-L1 IHC 22C3 pharmDx assay and the VENTANA PD-L1 (SP263) IHC assay (Hirsch et al., J. Thorac. Oncol. 12(2):208-22(2017); Ratcliffe et al., Clin. Cancer Res. 23(14):3585-91(2017)).
[0042] Tumor response was assessed by BICR using RECIST v1.1 with imaging performed every 6 weeks for the first 48 weeks, then every 8 weeks until disease progression was confirmed. Patients were followed for survival. AEs were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 4.03.
[0043] Blood TMB was assessed using the Guardant OMNI next-generation sequencing platform (Guardant Health, Redwood City, CA, USA), which consists of 500 genes (Figure 1). All genes shown in Figure 1 are potential identifiers of TMB, and the relevance of each gene or combination of genes varies across patients.
[0044] The OMNI TMB algorithm incorporates somatic single nucleotide variants (SNVs), short insertions / deletions (indels), copy number amplifications and fusions and is optimized to calculate TMB in blood samples with low cell-free circulating tumor DNA content (Merck Sharp & Dohme. Summary of Product Characteristics for Keytruda® (Pembrolizumab). Updated March 2019. Available at: https: / / www.medicines.org.uk / emc / product / 6947 / smpc (last accessed May 1, 2019); Reck et al., N. Engl. J. Med. 375(19):1823-33(2016)). Both synonymous and nonsynonymous SNVs and indels were included and those with low shedding values, low diversity, and those associated with clonal hematopoiesis, germline and oncogenic drivers or drug resistance mechanisms were excluded. Tissue TMB was assessed using the FoundationOne tissue next-generation sequencing platform (Foundation Medicine, Cambridge, MA, USA) using an algorithm previously described (Merck Sharp & Dohme. Keytruda® (pembrolizumab) prescribing information. Updated April 2019. Available at: https: / / www.merck.com / product / usa / pi_circulars / k / keytruda / keytruda_pi.pdf (last accessed May 1, 2019)).
[0045] statistical analysis Approximately 1092 patients, including 480 with PD-L1 TC ≥ 25%, were required to generate 231 PFS events in the primary PFS analysis in the durvalumab plus tremelimumab and chemotherapy arms, and 225 OS events in the primary OS analysis comparing each treatment group.
[0046] Efficacy was analyzed on an intention-to-treat (ITT) basis, including all randomized patients or subpopulations of this population based on PD-L1 expression or TMB levels. Safety analyses included all patients who received at least one dose of study treatment (as the treated population). A hierarchical multiple testing procedure was used with a gatekeeping strategy across endpoints, analysis populations, and treatment regimens to control type I errors to 5% (two-sided). Primary PFS analyses were performed using a stratified log-rank test, adjusting for histology, with hazard ratios (HRs) and 99.5% confidence intervals (CIs) estimated using a Cox proportional hazards model. Primary OS analyses were performed using a similar method, with HRs estimated at two-sided 97.54% Ci and 98.77% Ci for comparing durvalumab and the combination of durvalumab and tremelimumab with chemotherapy, respectively. Survival curves were constructed using the Kaplan-Meier method.
[0047] In secondary analyses performed in the PD-L1 TC ≥ 1% and ITT populations, stratification was additionally adjusted for PD-L1 expression status (TC ≥ 25% vs. TC < 25%). Odds ratios and 95% CIs for comparing ORR between treatment arms were calculated using logistic regression models, adjusted for the same factors as for PFS and OS. Prespecified TMB analyses were performed using the unstratified log-rank test, with HRs and 95% CIs estimated using the Cox proportional hazards model.
[0048] result Of 1118 randomized patients, 1092 (97.7%) received at least one dose of study treatment (369 durvalumab, 371 durvalumab plus tremelimumab, and 352 chemotherapy). In the chemotherapy group, the most common regimens were gemcitabine plus carboplatin (49.5%) and pemetrexed plus carboplatin (54.5%) in patients with squamous and nonsquamous histology, respectively. A total of 488 patients had PD-L1 TC ≥ 25% (primary analysis population; 43.6% of randomized patients). Baseline demographic and disease characteristics of patients with PD-L1 TC ≥ 25% were closely matched to the ITT population and were well balanced between treatment arms.
[0049] Among patients with PD-L1 TC ≥ 25%, 25 patients in the durvalumab arm, 18 in the durvalumab plus tremelimumab arm, and 1 in the chemotherapy arm continued study treatment. Of these patients, 5 in the durvalumab arm and 1 in the durvalumab plus tremelimumab arm remained on treatment until progression, and 5 in the durvalumab plus tremelimumab arm were re-treated with tremelimumab. After discontinuation of study treatment, 73 patients (44.8%) in the durvalumab arm, 61 (37.4%) in the durvalumab plus tremelimumab arm, and 95 (58.6%) in the chemotherapy arm subsequently received systemic cancer treatment. Of these patients, 10 of 73 (13.7%) in the durvalumab group, 5 of 61 (8.2%) in the durvalumab plus tremelimumab group, and 64 of 95 (67.4%) in the chemotherapy group received immunotherapy.
[0050] 1. Effectiveness Median OS with follow-up was 30.2 months (range, 0.3-37.2). In patients with PD-L1 TC ≥ 25%, durvalumab and the combination of durvalumab and tremelimumab did not result in a statistically significant improvement in OS compared with chemotherapy. Median OS was 16.3 months with durvalumab versus 12.9 months with chemotherapy (HR for death, 0.76; 97.54% CI, 0.56-1.02; P = 0.036) (Figure 2). 24-month OS rates were 38.3% (95% CI, 30.7-45.7) in the durvalumab group versus 22.7% (16.5-29.5) with chemotherapy. The most planned subgroup of patients treated with durvalumab had a numerical improvement in OS compared with chemotherapy (Figure 4). With durvalumab plus tremelimumab, the median OS was 11.9 months, with a 24-month OS rate of 35.4% (95% CI, 28.1–42.8) (HR for death vs. chemotherapy, 0.85; 98.77% CI, 0.61–1.17; P = 0.202) ( Fig. 2 ). OS within the ITT population and within subgroups defined by different PD-L1 expression levels (TC < 1%, ≥ 1%, ≥ 25–49%, and ≥ 50%) is shown in Table 1 .
[0051] [Table 1]
[0052] The median PFS with follow-up was 10.6 months (range, 0-18). There was no statistically significant difference in PFS between the durvalumab and chemotherapy groups (secondary endpoint; Figure 3) or between the durvalumab plus tremelimumab and chemotherapy groups (primary endpoint; Figure 3). Median PFS was 3.9 months (95% CI, 2.8-5.0) with durvalumab plus tremelimumab versus 5.4 months (4.6-5.8) with chemotherapy (HR for disease progression or death, 1.05; 99.5% CI, 0.72-1.53; P = 0.705); 12-month PFS rates were 25.8% (95% CI, 18.9-33.1) with durvalumab plus tremelimumab versus 14.3% (8.4-21.7) with chemotherapy.
[0053] In patients with PD-L1 TC ≥ 25%, the ORR was 35.6% in the durvalumab group, 34.4% in the durvalumab plus tremelimumab group, and 37.7% in the chemotherapy group (Table 2). The median DOR was not reached in the immunotherapy group compared with 4.4 months in the chemotherapy group. At 12 months, more patients in the immunotherapy-treated groups had sustained responses (61.3%, 54.9%, and 18.0% in the durvalumab, durvalumab plus tremelimumab, and chemotherapy groups, respectively) (Table 2).
[0054] [Table 2]
[0055] Of 1118 randomized patients, pretreatment blood and tissue samples from 809 (72%) and 460 (41%) patients, respectively, were evaluable for TMB. TMB values did not correlate with PD-L1 expression levels (blood: Spearman rank correlation coefficient = 0.05, Pearson correlation coefficient = 0.01; tissue: Spearman rank correlation coefficient = 0.09, Pearson correlation coefficient = 0.06). In patients with both matched samples (n = 352; 31% of randomized patients), bTMB and tTMB were correlated (Spearman rank correlation coefficient = 0.6, Pearson correlation coefficient = 0.7; Figure 5). Baseline characteristics of the bTMB- and tTMB-evaluable populations were consistent with the ITT population and balanced between treatment arms. OS of the TMB-evaluable population was consistent with the ITT population across the three treatment arms (Figures 6A-6C). HRs of death improved progressively for durvalumab plus tremelimumab versus chemotherapy with increasing bTMB thresholds (Figures 7-8). Blood TMB ≥ 20 mut / Mb was selected for further analysis based on a clinically meaningful effect size for the durvalumab plus tremelimumab combination and the patient population that would benefit. Relatedly, tTMB ≥ 10 mut / Mb was tested based on a threshold shown to be predictive of PFS and response in previous studies of nivolumab plus ipilimumab in NSCLC (Hellmann et al., N. Engl. J. Med. 378(22):2093-104(2018); Ready et al., J. Clin. Oncol. 37(12):992-1000(2019)). Further analysis at tTMB thresholds above 10 mut / Mb was limited by small sample size. A greater proportion of patients with a smoking history and squamous histology were present in patients with bTMB ≥ 20mut / Mb or tTMB ≥ 10 compared with the corresponding lower TMB subgroups. Intersection between the bTMB ≥ 20mut / Mb and PD-L1 TC ≥ 25% populations was minimal (9% of randomized patients; Figure 9).
[0056] Blood TMB ≥ 20mut / Mb was associated with improved OS for durvalumab plus tremelimumab versus chemotherapy (median, 21.9 vs. 10.0 months; unadjusted HR for death, 0.49 [95% CI, 0.32-0.74]; Figure 10); 24-month OS rates were 48.1% (95% CI, 35.5-59.7) for durvalumab plus tremelimumab versus 19.4% (11.0-29.5) for chemotherapy. In contrast, there was no improved OS for durvalumab plus tremelimumab versus chemotherapy in patients with bTMB < 20mut / Mb (median, 8.5 vs. 11.6 months; unadjusted HR for death, 1.16 [95% CI, 0.93-1.45]; Figure 10). Blood TMB ≥ 20 mut / Mb but not bTMB < 20 mut / Mb was also associated with improved PFS (Figure 11) and ORR (Table 3) for durvalumab plus tremelimumab versus chemotherapy.
[0057] [Table 3]
[0058] For patients with bTMB ≥ 20mut / Mb receiving durvalumab alone, median OS was 12.6 months (unadjusted HR for death vs chemotherapy, 0.72; 95% CI, 0.50-1.05). For durvalumab plus tremelimumab vs durvalumab, the HR for death was 0.74 (95% CI, 0.48-1.11; Figure 10), supporting the additional contribution of tremelimumab.
[0059] Tissue TMB ≥ 10 mut / Mb but not tTMB < 10 mut / Mb was associated with numerically longer OS in both immunotherapy versus chemotherapy arms. Median OS was 16.6 months for durvalumab plus tremelimumab, 18.6 months for durvalumab, and 11.9 months for chemotherapy. HR for death was 0.72 (95% CI, 0.48-1.09) for durvalumab plus tremelimumab versus chemotherapy and 0.70 (0.47-1.06) for durvalumab versus chemotherapy (Figures 12A-12B).
[0060] Two blood-based algorithms showed improved outcomes for D+T compared to chemotherapy (V2 and V3; see Figure 13). The V2 algorithm was chosen because it is simpler than V3, but both showed similar predictability.
[0061] For D+T in MYSTIC, TMB was more predictive of OS than PD-L1 expression level, regardless of the cut point used. This did not correlate with high PD-L1 expression, thus identifying a unique patient subpopulation with bTMB (Figure 9). Additionally, combining bTMB with PD-L1 expression increases patient prevalence but reduces effect size (Figures 16 and 17).
[0062] 2. Safety The median duration of treatment was 16.0 weeks (range, 0.4-148.6) for durvalumab; 16.0 weeks (0.6-161.3) and 12.0 weeks (0.6-32.0) for durvalumab and tremelimumab, respectively, in the combination group; and 17.9 weeks (1.1-137.4) for chemotherapy.
[0063] AEs of any grade determined by the investigator to be treatment-related (TRAEs) occurred in 54.2%, 60.1%, and 83.0% of patients treated with durvalumab, the combination of durvalumab and tremelimumab, and chemotherapy, respectively. Rates of grade ≥3 TRAEs were lower with durvalumab (14.9%) and the combination of durvalumab and tremelimumab (22.9%) compared with chemotherapy (33.8%), and fewer patients in the durvalumab group experienced TRAEs leading to discontinuation (5.4% vs. 13.2% and 9.4%, respectively). Treatment-related deaths occurred in two patients (0.5%) in the durvalumab group, six (1.6%) in the combination of durvalumab and tremelimumab, and three (0.9%) in the chemotherapy group. Safety in the primary analysis population with PD-L1 TC ≥ 25% and in the bTMB ≥ 20mut / Mb population was consistent with the full safety evaluation population.
[0064] Immune-mediated AEs were reported in 13.6% of patients in the durvalumab group, 28.3% in the durvalumab plus tremelimumab group, and 3.4% in the chemotherapy group. These events were grade 3 or 4 in 4.1%, 10.8%, and 0.6% of patients, respectively.
[0065] The analysis identified a bTMB threshold of ≥20 mut / Mb for optimal OS benefit with durvalumab in combination with tremelimumab in this study, as well as clinically meaningful improvements in both PFS and response.
[0066] Example 2: ctDNA mutations associated with sensitivity or resistance to immunotherapy in mNSCLC: Analysis from the MYSTIC study In this example, the relationship between selected mutations and survival outcomes was investigated. Circulating tumor DNA from baseline plasma samples was profiled using the GuardantOMNI platform. Samples were available from 1003 patients (89.7% of the ITT population). 943 samples were evaluable for mutations. Survival outcomes were analyzed in patients with or without nonsynonymous somatic mutations in STK11, KEAP1, or ARID1A, or KRAS.
[0067] The study demonstrated that across treatment arms, patients with metastatic NSCLC ("mNSCLC") and mutations in the serine / threonine kinase 11 gene (STK11) or Kelch-like ECH-associated protein 1 gene (KEAP1) had a more poor outcome compared to patients without the corresponding mutations. In patients receiving D+T, AT-rich interaction domain-containing protein 1A gene mutations (ARID1Am) were associated with a survival benefit compared to the AT-rich interaction domain-containing protein 1A wild-type gene (ARID1wt).
[0068] In the mutation-evaluable population, the frequencies of STK11m, KEAP1m, and ARID1Am were 16%, 18%, and 12%, respectively (19%, 20%, and 11% [nonsquamous]; 7%, 13%, and 15% [squamous]) (Figures 18-21). In each treatment group, patients with STK11m or KEAP1m had shorter median OS ("mOS") than mNSCLC patients with STK11wt (D, 10.3 vs. 13.3 months; D+T, 4.4 vs. 11.3 months; CT, 6.7 vs. 13.1 months) or KEAP1wt (D, 7.6 vs. 14.6 months; D+T, 9.2 vs. 11.3 months; CT, 6.3 vs. 13.3 months) (Figures 22-27). In the D+T group, patients with ARID1Am had longer mOS than mNSCLC patients with ARID1Awt (D, 8.6 vs. 13.7 months; D+T, 23.2 vs. 9.8 months; CT, 10.6 vs. 12.4 months) (Figures 28-29).
[0069] All patents and publications mentioned in this specification are herein incorporated by reference to the same extent as if each individual patent and publication was specifically and individually indicated to be incorporated by reference. Citation or identification of any reference in any section of this application shall not be construed as an admission that such reference is available as prior art to the present invention. The present invention includes, for example, the following embodiments: [Embodiment 1] A method for predicting the success of a cancer treatment in a patient in need thereof, the method comprising a step of determining the tumor mutation burden (TMB) of the patient, wherein a high TMB predicts the success of the treatment. [Embodiment 2] The method of embodiment 1, wherein high TMB is defined as ≧12 to ≧20 mutations / megabase (mut / Mb). [Embodiment 3] The method of embodiment 2, wherein high TMB is defined as ≧16 mutations / megabase (mut / Mb). [Embodiment 4] The method of embodiment 2, wherein high TMB is defined as ≧20 mutations / megabase (mut / Mb).
[0024]
[0025] The method of embodiment 1, wherein the treatment of the cancer comprises treatment with durvalumab.
[0024]
[0025]
[0026] The method of embodiment 5, wherein the treatment of the cancer further comprises treatment with tremelimumab. [Embodiment 7] The method of embodiment 5 or embodiment 6, wherein the treatment of the cancer further comprises treatment with a chemotherapeutic agent. [Embodiment 8] The method of embodiment 7, wherein the chemotherapeutic agent comprises at least one of Abraxane, carboplatin, gemcitabine, cisplatin, pemetrexed, or paclitaxel. [Embodiment 9] The method of embodiment 1, wherein the patient has a somatic mutation in at least one of the serine / threonine kinase 11 gene (STK11), the Kelch-like ECH-associated protein 1 gene (KEAP1), the AT-rich interaction domain-containing protein 1A gene (ARID1A), or the K-Ras gene.
[0036] [Embodiment 10] A method for treating cancer in a patient in need thereof, comprising: (a) determining the TMB of the patient; (b) determining whether the TMB is high or low; and (c) treating or continuing treatment if TMB is high, or not treating or discontinuing treatment if TMB is low. The method includes: [Embodiment 11] The method of embodiment 10, wherein high TMB is defined as ≧12 to ≧20 mutations / megabase (mut / Mb). [Embodiment 12] The method of embodiment 11, wherein high TMB is defined as ≧16 mutations / megabase (mut / Mb). [Embodiment 13] The method of embodiment 11, wherein high TMB is defined as ≧20 mutations / megabase (mut / Mb). [Embodiment 14] The method of embodiment 10, wherein the treatment comprises treatment with durvalumab. [Embodiment 15] The method of embodiment 14, wherein the treatment further comprises treatment with tremelimumab. [Embodiment 16] The method of embodiment 14 or embodiment 15, wherein the treatment further comprises treatment with a chemotherapeutic agent. [Embodiment 17] The method of embodiment 16, wherein the chemotherapeutic agent comprises at least one of Abraxane, carboplatin, gemcitabine, cisplatin, pemetrexed, or paclitaxel. [Embodiment 18] The method of embodiment 1 or embodiment 10, wherein successful treatment is determined by an increase in OS compared to standard treatment. [Embodiment 19] The method described in embodiment 10, wherein the patient has a somatic mutation in at least one of the serine / threonine kinase 11 gene (STK11), the Kelch-like ECH-associated protein 1 gene (KEAP1), the AT-rich interaction domain-containing protein 1A gene (ARID1A), or the K-Ras gene. [Embodiment 20] A method for predicting the success of cancer treatment in a patient in need thereof, the method comprising a step of determining whether the patient has a somatic mutation in the AT-rich interaction domain-containing protein 1A gene (ARID1A), and where the presence of a somatic mutation predicts the success of the treatment. [Embodiment 21] The method of embodiment 20, wherein the treatment of the cancer comprises treatment with durvalumab. [Embodiment 22] The method of embodiment 20, wherein the treatment of the cancer further comprises treatment with tremelimumab. [Embodiment 23] The method of embodiment 21 or embodiment 22, wherein the treatment of the cancer further comprises treatment with a chemotherapeutic agent. [Embodiment 24] The method of embodiment 23, wherein the chemotherapeutic agent comprises at least one of Abraxane, carboplatin, gemcitabine, cisplatin, pemetrexed, or paclitaxel. [Embodiment 25] A method for treating cancer in a patient in need thereof, comprising: (a) determining whether the patient has a somatic mutation in at least one of the serine / threonine kinase 11 gene (STK11), the Kelch-like ECH-associated protein 1 gene (KEAP1), the AT-rich interaction domain-containing protein 1A gene (ARID1A), or the K-Ras gene; and (b) administering or continuing the treatment if the patient has a somatic mutation in at least one of the serine / threonine kinase 11 gene (STK11), the Kelch-like ECH-associated protein 1 gene (KEAP1), the AT-rich interaction domain-containing protein 1A gene (ARID1A), or the K-Ras gene. The method includes: [Embodiment 26] The method of embodiment 25, wherein the treatment comprises treatment with durvalumab. [Embodiment 27] The method of embodiment 26, wherein the treatment further comprises treatment with tremelimumab. [Embodiment 28] The method of embodiment 26 or embodiment 27, wherein the treatment further comprises treatment with a chemotherapeutic agent. [Embodiment 29] The method of embodiment 28, wherein the chemotherapeutic agent comprises at least one of Abraxane, carboplatin, gemcitabine, cisplatin, pemetrexed, or paclitaxel.
Claims
1. 1. A method for predicting success of a cancer treatment in a patient in need thereof, the method comprising determining the tumor mutation burden (TMB) of the patient, wherein a high TMB predicts success of the treatment.
2. 2. The method of claim 1, wherein high TMB is defined as ≧12 to ≧20 mutations per megabase (mut / Mb).
3. 3. The method of claim 2, wherein high TMB is defined as >= 16 mutations / megabase (mut / Mb).
4. 3. The method of claim 2, wherein high TMB is defined as >= 20 mutations / megabase (mut / Mb).
5. 2. The method of claim 1, wherein the treatment of cancer comprises treatment with durvalumab.
6. 6. The method of claim 5, wherein the treatment of cancer further comprises treatment with tremelimumab.
7. 7. The method of claim 5 or claim 6, wherein the treatment of cancer further comprises treatment with a chemotherapeutic agent.
8. 8. The method of claim 7, wherein the chemotherapeutic agent comprises at least one of Abraxane, carboplatin, gemcitabine, cisplatin, pemetrexed, or paclitaxel.
9. 2. The method of claim 1, wherein the patient has a somatic mutation in at least one of the serine / threonine kinase 11 gene (STK11), the Kelch-like ECH-binding protein 1 gene (KEAP1), the AT-rich interaction domain-containing protein 1A gene (ARID1A), or the K-Ras gene.
10. 1. A method of treating cancer in a patient in need thereof, comprising: (a) determining the patient's TMB; (b) determining whether the TMB is high or low; and (c) administering treatment or continuing treatment if TMB is high, or not administering treatment or discontinuing treatment if TMB is low. The method includes:
11. 11. The method of claim 10, wherein high TMB is defined as ≧12 to ≧20 mutations per megabase (mut / Mb).
12. 12. The method of claim 11, wherein high TMB is defined as >= 16 mutations / megabase (mut / Mb).
13. 12. The method of claim 11, wherein high TMB is defined as > 20 mutations / megabase (mut / Mb).
14. 11. The method of claim 10, wherein the treatment comprises treatment with durvalumab.
15. 15. The method of claim 14, wherein the treatment further comprises treatment with tremelimumab.
16. 16. The method of claim 14 or claim 15, wherein the treatment further comprises treatment with a chemotherapeutic agent.
17. 17. The method of claim 16, wherein the chemotherapeutic agent comprises at least one of Abraxane, carboplatin, gemcitabine, cisplatin, pemetrexed, or paclitaxel.
18. 11. The method of claim 1 or claim 10, wherein successful treatment is determined by an increase in OS when compared to standard of care.
19. 11. The method of claim 10, wherein the patient has a somatic mutation in at least one of the serine / threonine kinase 11 gene (STK11), the Kelch-like ECH-binding protein 1 gene (KEAP1), the AT-rich interaction domain-containing protein 1A gene (ARID1A), or the K-Ras gene.
20. 1. A method for predicting success of cancer treatment in a patient in need thereof, the method comprising a step of determining whether the patient has a somatic mutation in the AT-rich interaction domain-containing protein 1A gene (ARID1A), wherein success of the treatment is predicted if there is a somatic mutation.
21. 21. The method of claim 20, wherein the treatment of cancer comprises treatment with durvalumab.
22. 21. The method of claim 20, wherein the treatment of cancer further comprises treatment with tremelimumab.
23. 23. The method of claim 21 or claim 22, wherein the treatment of cancer further comprises treatment with a chemotherapeutic agent.
24. 24. The method of claim 23, wherein the chemotherapeutic agent comprises at least one of Abraxane, carboplatin, gemcitabine, cisplatin, pemetrexed, or paclitaxel.
25. 1. A method of treating cancer in a patient in need thereof, comprising: (a) determining whether the patient has a somatic mutation in at least one of the serine / threonine kinase 11 gene (STK11), the Kelch-like ECH-binding protein 1 gene (KEAP1), the AT-rich interaction domain-containing protein 1A gene (ARID1A), or the K-Ras gene; and (b) administering or continuing treatment if the patient has a somatic mutation in at least one of the serine / threonine kinase 11 gene (STK11), the Kelch-like ECH-binding protein 1 gene (KEAP1), the AT-rich interaction domain-containing protein 1A gene (ARID1A), or the K-Ras gene. The method includes:
26. 26. The method of claim 25, wherein the treatment comprises treatment with durvalumab.
27. 27. The method of claim 26, wherein the treatment further comprises treatment with tremelimumab.
28. 28. The method of claim 26 or claim 27, wherein the treatment further comprises treatment with a chemotherapeutic agent.
29. 29. The method of claim 28, wherein the chemotherapeutic agent comprises at least one of Abraxane, carboplatin, gemcitabine, cisplatin, pemetrexed, or paclitaxel.
Citation Information
Patent Citations
Neoantigens and methods of their use
WO2017173321A1
